Learn about plans for clinical evaluation of ARAKODA® (tafenoquine) for COVID-19 disease.
WATCH NOW
LATEST HEADLINES
Positive Phase II Study Data Suggest ARAKODA® (tafenoquine) Numerically Improved Clinical Recovery in Patients with Mild-Moderate COVID-19 Disease
Developing therapeutic innovations that can significantly improve and extend people’s lives.
In 2010, 60° Pharmaceuticals began its mission to build a better world by undertaking research and action focused on aiding in the prevention of tropical diseases.
Escalating malaria care
to people in need around
the world
Advancing therapies for the treatment and prevention of malaria.
Meeting the challenges of
the global dengue endemic
With only one vaccine commercially available in the US to effectively combat dengue fever, 60P is poised to enter the dengue fever treatment arena.
For the investment community
We are committed to serving the best interests of our investors.
Our team is committed to creating innovative, potentially lifesaving medicines to significantly impact the quality of life for those affected by tropical diseases worldwide.
405,000
Annual deaths from malaria globally
125,000,000
Travelers to endemic regions per annum
390,000,000
Dengue infections per year
202-327-5422
1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036